<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-AOG8XJ8F</identifier><date>2013</date><creator>Marc, Janja</creator><creator>Pajič, Tadej</creator><creator>Preložnik-Zupan, Irena</creator><relation>documents/doc/A/URN_NBN_SI_doc-AOG8XJ8F_001.htm</relation><relation>documents/doc/A/URN_NBN_SI_doc-AOG8XJ8F_001.pdf</relation><relation>documents/doc/A/URN_NBN_SI_doc-AOG8XJ8F_001.txt</relation><format format_type="issue">5</format><format format_type="volume">64</format><format format_type="type">article</format><format format_type="extent">str. 343-353</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="URN">0014-8229</identifier><identifier identifier_type="COBISSID">27314727</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="eng">drug</subject><subject language_type_id="slv">kronična mieloična levkemija</subject><subject language_type_id="eng">therapy</subject><subject language_type_id="slv">zdravila</subject><subject language_type_id="slv">zdravljenje</subject><title>Chronic myeloid leukemia</title><title>Kronična mieloična levkemija</title></Record>